BR112021024835A2 - Tratamento para sinuclenopatias - Google Patents

Tratamento para sinuclenopatias

Info

Publication number
BR112021024835A2
BR112021024835A2 BR112021024835A BR112021024835A BR112021024835A2 BR 112021024835 A2 BR112021024835 A2 BR 112021024835A2 BR 112021024835 A BR112021024835 A BR 112021024835A BR 112021024835 A BR112021024835 A BR 112021024835A BR 112021024835 A2 BR112021024835 A2 BR 112021024835A2
Authority
BR
Brazil
Prior art keywords
synuclenopathies
treatment
treating
compound
formula
Prior art date
Application number
BR112021024835A
Other languages
English (en)
Inventor
Michael Goldfine Andrew
Krishnaji Damle Nitin
Nandlal Mandhane Sanjaykumar
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of BR112021024835A2 publication Critical patent/BR112021024835A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

tratamento para sinuclenopatias. método de tratamento ou prevenção de sinucleinopatias em um indivíduo humano, caracterizado pelo fato de que compreende a administração de uma quan-tidade terapeuticamente eficaz de um composto de fórmula 1, ou seu sal farmaceuticamente aceitável.
BR112021024835A 2019-06-11 2020-06-09 Tratamento para sinuclenopatias BR112021024835A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921023164 2019-06-11
PCT/IB2020/055425 WO2020250133A1 (en) 2019-06-11 2020-06-09 Treatment for synucleinopathies

Publications (1)

Publication Number Publication Date
BR112021024835A2 true BR112021024835A2 (pt) 2022-01-18

Family

ID=71094647

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024835A BR112021024835A2 (pt) 2019-06-11 2020-06-09 Tratamento para sinuclenopatias

Country Status (14)

Country Link
US (1) US20220257582A1 (pt)
EP (1) EP3982964A1 (pt)
JP (1) JP2022536331A (pt)
KR (1) KR20220024463A (pt)
CN (1) CN114040763A (pt)
AU (1) AU2020292703A1 (pt)
BR (1) BR112021024835A2 (pt)
CA (1) CA3142899A1 (pt)
CL (1) CL2021003303A1 (pt)
EA (1) EA202193211A1 (pt)
IL (1) IL288797A (pt)
MA (1) MA56179A (pt)
MX (1) MX2021015390A (pt)
WO (1) WO2020250133A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214314A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Vodobatinib for reducing progression of parkinson's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057165A2 (en) 2002-01-04 2003-07-17 The Rockefeller University COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
US20060128720A1 (en) 2002-03-21 2006-06-15 Kufe Donald W Inhibition of cell death responses induced by oxidative stress
TWI343806B (en) 2003-07-01 2011-06-21 Nat Health Research Institutes Methods of inhibiting neurodegenerative disease
US8618063B2 (en) 2008-04-09 2013-12-31 The Board Of Trustees Of The University Of Illinois Method for treating a synucleinopathy
ES2608829T3 (es) 2011-01-21 2017-04-17 Sun Pharma Advanced Research Company Limited Inhibidores de tirosina quinasa que contienen diarilacetileno hidrazida
BR112013024171A2 (pt) 2011-04-07 2016-12-13 Ariad Pharma Inc método para o tratamento e prevenção de uma condição neurodegenerativa
EP2844256B1 (en) 2012-05-02 2023-02-22 Georgetown University Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors
CA3024976A1 (en) 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease

Also Published As

Publication number Publication date
WO2020250133A1 (en) 2020-12-17
CL2021003303A1 (es) 2022-08-19
US20220257582A1 (en) 2022-08-18
JP2022536331A (ja) 2022-08-15
IL288797A (en) 2022-02-01
AU2020292703A1 (en) 2022-01-27
EP3982964A1 (en) 2022-04-20
CN114040763A (zh) 2022-02-11
KR20220024463A (ko) 2022-03-03
MA56179A (fr) 2022-04-20
MX2021015390A (es) 2022-01-24
EA202193211A1 (ru) 2022-03-30
CA3142899A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
ZA202109010B (en) Compounds and methods for the treatment of covid-19
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
BR112019024831A2 (pt) composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
BR112022008020A2 (pt) Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1
EA202090604A1 (ru) Хроманмонобактамовые соединения для лечения бактериальных инфекций
AR060089A1 (es) Tratamiento del dolor
PH12019500177A1 (en) Treatment and prevention of sleep disorders
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
WO2020033838A3 (en) Treatment of egfr-mutant cancer
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
AR119159A1 (es) Tratamientos de angioedema
BR112022000231A2 (pt) Novos métodos
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2022010258A (es) Composiciones y métodos para tratar la lesión renal.
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
BR112021024835A2 (pt) Tratamento para sinuclenopatias
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
MX2022003845A (es) Tratamientos cognitivos medicinales.
EA202193276A1 (ru) Способы лечения холангиокарциномы
BR112015012497A2 (pt) combinações farmacêuticas
BR112018002763A2 (pt) método para cicatrização de ferimentos
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
BR112023023702A2 (pt) Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga
BR112019005217A2 (pt) terapia combinada